bokomslag Cellular Therapies for Retinal Disease
Kropp & själ

Cellular Therapies for Retinal Disease

Steven D Schwartz Aaron Nagiel Robert Lanza

Inbunden

2159:-

Funktionen begränsas av dina webbläsarinställningar (t.ex. privat läge).

Uppskattad leveranstid 7-12 arbetsdagar

Fri frakt för medlemmar vid köp för minst 249:-

Andra format:

  • 143 sidor
  • 2017
This book familiarizes the reader with the current landscape of cell-based therapies for the treatment of retinal disease, including diseases that affect the choriocapillaris, retinal pigment epithelium, photoreceptors, and retinal ganglion cells. Instead of utilizing a disease-centric approach to the topic, this bookedited by two world-renowned stem cell scientistsfocuses on strategies for developing and transplanting the cells. This includes the creation of replacement cells, cell-based neuroprotection, and in vitro disease modeling and testing. The final chapters briefly review parallel approaches that do not directly utilize cellular transplantation. The use of cellular transplantation to treat retinal disease has recently become a viable and exciting therapeutic approach. The visibility of the retina and its laminar cellular architecture render it an ideal organ for the development of surgically delivered cellular therapies. Having an in-depth understanding ofthe current state of cell therapy for the eye is an essential first step toward utilizing similar approaches in other organs. Ophthalmologists, translational clinician-scientists, stem cell scientists, and researchers interested in eye disease will find Cellular Therapies for Retinal Disease: A Strategic Approach essential reading and it is also suitable for workshops or courses at the undergraduate or Ph.D. level.
  • Författare: Steven D Schwartz, Aaron Nagiel, Robert Lanza
  • Illustratör: Bibliographie 5 schwarz-weiße und 38 farbige Abbildungen
  • Format: Inbunden
  • ISBN: 9783319494777
  • Språk: Engelska
  • Antal sidor: 143
  • Utgivningsdatum: 2017-07-06
  • Förlag: Springer International Publishing AG